Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer
Current treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients progressing beyond first-line (1L) treatment. With new treatments under investigation, understanding current treatment patterns, the impact of newly approved therapi...
Uložené v:
| Vydané v: | Gynecologic oncology Ročník 164; číslo 3; s. 645 - 650 |
|---|---|
| Hlavní autori: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
Elsevier Inc
01.03.2022
|
| Predmet: | |
| ISSN: | 0090-8258, 1095-6859, 1095-6859 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Current treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients progressing beyond first-line (1L) treatment. With new treatments under investigation, understanding current treatment patterns, the impact of newly approved therapies, and total costs of care for r/mCC are important.
A retrospective analysis of a US commercial insurance claims database to identify adult patients with r/mCC between 2015 and Q1–2020; defining 1L treatment as the first administration of systemic treatment without concomitant chemoradiation or surgery. Patient characteristics, treatment regimens, duration of therapy, and total costs of care were evaluated for each line of therapy.
1323 women initiated 1L treatment for r/mCC (mean age, 56.1 years; mean follow-up, 16.5 months). One-third (n = 438) had evidence of second-line (2L) treatment; of these, 129 (29%) had evidence of third-line (3L) treatment. No regimen represented a majority among 2L+ treatments. The 2018 approval of pembrolizumab led to increased 2L immunotherapy use (0% in 2015, 37% in 2019/Q1–2020). However, only a small proportion of patients stayed on immunotherapy for a prolonged period. Mean per-patient-per-month total costs of care during treatment were $47,387 (1L), $77,661 (2L), and $53,609 (3L), driven primarily by outpatient costs.
No clear standard of care was observed in 2L+. Although immunotherapy is increasingly used in 2L+, only a small subset of patients stayed on immunotherapy for a prolonged period, suggesting a need for more therapeutic options. Better understanding of disease biology and the introduction of new therapies may address these unmet needs.
•There is no clear standard of care observed in 2L+ r/mCC.•Immunotherapy use in 2L increased from 0% in 2015 to 37% in Q1 2020.•However, only a small proportion stayed on immunotherapy for a prolonged period.•Average costs per patient per month across lines ranged from $47,000 to $77,000.•Therapeutic options with differentiated modalities are needed for 2L+ patients. |
|---|---|
| AbstractList | Current treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients progressing beyond first-line (1L) treatment. With new treatments under investigation, understanding current treatment patterns, the impact of newly approved therapies, and total costs of care for r/mCC are important.
A retrospective analysis of a US commercial insurance claims database to identify adult patients with r/mCC between 2015 and Q1–2020; defining 1L treatment as the first administration of systemic treatment without concomitant chemoradiation or surgery. Patient characteristics, treatment regimens, duration of therapy, and total costs of care were evaluated for each line of therapy.
1323 women initiated 1L treatment for r/mCC (mean age, 56.1 years; mean follow-up, 16.5 months). One-third (n = 438) had evidence of second-line (2L) treatment; of these, 129 (29%) had evidence of third-line (3L) treatment. No regimen represented a majority among 2L+ treatments. The 2018 approval of pembrolizumab led to increased 2L immunotherapy use (0% in 2015, 37% in 2019/Q1–2020). However, only a small proportion of patients stayed on immunotherapy for a prolonged period. Mean per-patient-per-month total costs of care during treatment were $47,387 (1L), $77,661 (2L), and $53,609 (3L), driven primarily by outpatient costs.
No clear standard of care was observed in 2L+. Although immunotherapy is increasingly used in 2L+, only a small subset of patients stayed on immunotherapy for a prolonged period, suggesting a need for more therapeutic options. Better understanding of disease biology and the introduction of new therapies may address these unmet needs.
•There is no clear standard of care observed in 2L+ r/mCC.•Immunotherapy use in 2L increased from 0% in 2015 to 37% in Q1 2020.•However, only a small proportion stayed on immunotherapy for a prolonged period.•Average costs per patient per month across lines ranged from $47,000 to $77,000.•Therapeutic options with differentiated modalities are needed for 2L+ patients. AbstractBackgroundCurrent treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients progressing beyond first-line (1L) treatment. With new treatments under investigation, understanding current treatment patterns, the impact of newly approved therapies, and total costs of care for r/mCC are important. MethodsA retrospective analysis of a US commercial insurance claims database to identify adult patients with r/mCC between 2015 and Q1–2020; defining 1L treatment as the first administration of systemic treatment without concomitant chemoradiation or surgery. Patient characteristics, treatment regimens, duration of therapy, and total costs of care were evaluated for each line of therapy. Results1323 women initiated 1L treatment for r/mCC (mean age, 56.1 years; mean follow-up, 16.5 months). One-third ( n = 438) had evidence of second-line (2L) treatment; of these, 129 (29%) had evidence of third-line (3L) treatment. No regimen represented a majority among 2L+ treatments. The 2018 approval of pembrolizumab led to increased 2L immunotherapy use (0% in 2015, 37% in 2019/Q1–2020). However, only a small proportion of patients stayed on immunotherapy for a prolonged period. Mean per-patient-per-month total costs of care during treatment were $47,387 (1L), $77,661 (2L), and $53,609 (3L), driven primarily by outpatient costs. ConclusionsNo clear standard of care was observed in 2L+. Although immunotherapy is increasingly used in 2L+, only a small subset of patients stayed on immunotherapy for a prolonged period, suggesting a need for more therapeutic options. Better understanding of disease biology and the introduction of new therapies may address these unmet needs. Current treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients progressing beyond first-line (1L) treatment. With new treatments under investigation, understanding current treatment patterns, the impact of newly approved therapies, and total costs of care for r/mCC are important.BACKGROUNDCurrent treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients progressing beyond first-line (1L) treatment. With new treatments under investigation, understanding current treatment patterns, the impact of newly approved therapies, and total costs of care for r/mCC are important.A retrospective analysis of a US commercial insurance claims database to identify adult patients with r/mCC between 2015 and Q1-2020; defining 1L treatment as the first administration of systemic treatment without concomitant chemoradiation or surgery. Patient characteristics, treatment regimens, duration of therapy, and total costs of care were evaluated for each line of therapy.METHODSA retrospective analysis of a US commercial insurance claims database to identify adult patients with r/mCC between 2015 and Q1-2020; defining 1L treatment as the first administration of systemic treatment without concomitant chemoradiation or surgery. Patient characteristics, treatment regimens, duration of therapy, and total costs of care were evaluated for each line of therapy.1323 women initiated 1L treatment for r/mCC (mean age, 56.1 years; mean follow-up, 16.5 months). One-third (n = 438) had evidence of second-line (2L) treatment; of these, 129 (29%) had evidence of third-line (3L) treatment. No regimen represented a majority among 2L+ treatments. The 2018 approval of pembrolizumab led to increased 2L immunotherapy use (0% in 2015, 37% in 2019/Q1-2020). However, only a small proportion of patients stayed on immunotherapy for a prolonged period. Mean per-patient-per-month total costs of care during treatment were $47,387 (1L), $77,661 (2L), and $53,609 (3L), driven primarily by outpatient costs.RESULTS1323 women initiated 1L treatment for r/mCC (mean age, 56.1 years; mean follow-up, 16.5 months). One-third (n = 438) had evidence of second-line (2L) treatment; of these, 129 (29%) had evidence of third-line (3L) treatment. No regimen represented a majority among 2L+ treatments. The 2018 approval of pembrolizumab led to increased 2L immunotherapy use (0% in 2015, 37% in 2019/Q1-2020). However, only a small proportion of patients stayed on immunotherapy for a prolonged period. Mean per-patient-per-month total costs of care during treatment were $47,387 (1L), $77,661 (2L), and $53,609 (3L), driven primarily by outpatient costs.No clear standard of care was observed in 2L+. Although immunotherapy is increasingly used in 2L+, only a small subset of patients stayed on immunotherapy for a prolonged period, suggesting a need for more therapeutic options. Better understanding of disease biology and the introduction of new therapies may address these unmet needs.CONCLUSIONSNo clear standard of care was observed in 2L+. Although immunotherapy is increasingly used in 2L+, only a small subset of patients stayed on immunotherapy for a prolonged period, suggesting a need for more therapeutic options. Better understanding of disease biology and the introduction of new therapies may address these unmet needs. Current treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients progressing beyond first-line (1L) treatment. With new treatments under investigation, understanding current treatment patterns, the impact of newly approved therapies, and total costs of care for r/mCC are important. A retrospective analysis of a US commercial insurance claims database to identify adult patients with r/mCC between 2015 and Q1-2020; defining 1L treatment as the first administration of systemic treatment without concomitant chemoradiation or surgery. Patient characteristics, treatment regimens, duration of therapy, and total costs of care were evaluated for each line of therapy. 1323 women initiated 1L treatment for r/mCC (mean age, 56.1 years; mean follow-up, 16.5 months). One-third (n = 438) had evidence of second-line (2L) treatment; of these, 129 (29%) had evidence of third-line (3L) treatment. No regimen represented a majority among 2L+ treatments. The 2018 approval of pembrolizumab led to increased 2L immunotherapy use (0% in 2015, 37% in 2019/Q1-2020). However, only a small proportion of patients stayed on immunotherapy for a prolonged period. Mean per-patient-per-month total costs of care during treatment were $47,387 (1L), $77,661 (2L), and $53,609 (3L), driven primarily by outpatient costs. No clear standard of care was observed in 2L+. Although immunotherapy is increasingly used in 2L+, only a small subset of patients stayed on immunotherapy for a prolonged period, suggesting a need for more therapeutic options. Better understanding of disease biology and the introduction of new therapies may address these unmet needs. |
| Author | Brouwer, Elizabeth Schwartz, Naomi R.M. Surinach, Andy Bloudek, Lisa Ramsey, Scott D. Ting, Jie Musa, Fernanda B. |
| Author_xml | – sequence: 1 givenname: Fernanda B. surname: Musa fullname: Musa, Fernanda B. organization: Swedish Cancer Institute, Seattle, WA, USA – sequence: 2 givenname: Elizabeth surname: Brouwer fullname: Brouwer, Elizabeth organization: Curta Inc., Seattle, WA, USA – sequence: 3 givenname: Jie surname: Ting fullname: Ting, Jie email: Jting@seagen.com organization: Seagen Inc., Bothell, WA, USA – sequence: 4 givenname: Naomi R.M. surname: Schwartz fullname: Schwartz, Naomi R.M. organization: Seagen Inc., Bothell, WA, USA – sequence: 5 givenname: Andy surname: Surinach fullname: Surinach, Andy organization: Genesis Research, Hoboken, NJ, USA – sequence: 6 givenname: Lisa surname: Bloudek fullname: Bloudek, Lisa organization: Curta Inc., Seattle, WA, USA – sequence: 7 givenname: Scott D. surname: Ramsey fullname: Ramsey, Scott D. organization: Fred Hutchinson Cancer Research Center, Seattle, WA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35031189$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFklFrFDEUhYNU7Lb6CwTJoy-73mRm0gRRKEVboeCD9Tlkkjtr1plkTbIr--_NuO1LQfsUuJzvXHLOPSMnIQYk5DWDFQMm3m1Wh_UhxBUHzlaMr4DLZ2TBQHVLITt1QhYACpaSd_KUnOW8AYAGGH9BTpsOGsakWhBzlzC4TH2gJaEpE4ZCt6YUTCFTExy1MZdM40CtSUjNFMN6FvgqzPS3Lz-ocXsTLDqai1kjtZj23pqxAnWaXpLngxkzvrp_z8n3z5_urm6Wt1-vv1xd3i5tK0RZXgzQdgCdGi64k2AE9E5Y18tGKmec7Xto-KDE4HpkXPGujtpBNRJF2zjVNufk7dF3m-KvHeaiJ58tjqMJGHdZc8EBJJOSV-mbe-mun9DpbfKTSQf9EEsVqKPApphzwkFbX-qfYyjJ-FEz0HMFeqP_VqDnCjTjulZQ2eYR-2D_f-rDkcIa0d5j0tnWiGuqPqEt2kX_BP_xEW9HH-YafuIB8ybuUqjpa6ZzBfS3-TTmy-CzoxKiGrz_t8GT6_8ApSnLDA |
| CitedBy_id | crossref_primary_10_1016_j_ygyno_2022_07_026 crossref_primary_10_1097_COC_0000000000001026 crossref_primary_10_1158_2767_9764_CRC_24_0647 crossref_primary_10_1177_15330338231202650 crossref_primary_10_1016_j_gore_2022_101101 crossref_primary_10_1016_j_gore_2022_101121 crossref_primary_10_1038_s41598_023_29821_4 crossref_primary_10_3390_cancers16051071 crossref_primary_10_1080_13543784_2023_2179483 crossref_primary_10_3389_fimmu_2024_1481584 crossref_primary_10_1016_j_ygyno_2022_12_004 crossref_primary_10_3389_fimmu_2025_1562875 crossref_primary_10_1371_journal_pone_0307282 |
| Cites_doi | 10.1200/JGO.2016.003954 10.1016/j.whi.2010.07.002 10.1097/MD.0000000000009125 10.1016/j.ygyno.2018.01.009 10.1136/jitc-2020-001126 10.1016/j.ygyno.2008.07.032 10.1016/j.ygyno.2017.02.011 10.20892/j.issn.2095-3941.2016.0015 10.1016/0360-3016(92)90671-4 10.1016/j.ajog.2015.07.022 10.1136/esmoopen-2018-000462 10.1080/03007995.2020.1758928 10.1016/j.ygyno.2021.03.002 10.1016/S1470-2045(19)30691-6 10.1093/annonc/mdx220 10.6004/jnccn.2020.0027 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Inc. Elsevier Inc. Copyright © 2022 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2022 Elsevier Inc. – notice: Elsevier Inc. – notice: Copyright © 2022 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ygyno.2021.12.028 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1095-6859 |
| EndPage | 650 |
| ExternalDocumentID | 35031189 10_1016_j_ygyno_2021_12_028 S0090825821016966 1_s2_0_S0090825821016966 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LG5 M29 M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 WUQ X7M XPP Z5R ZGI ZMT ZU3 ZXP ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c466t-7f0450059f72d80a60bd6cdb8389dadcbb032f96fdbe12925dcb4f938e643d943 |
| ISICitedReferencesCount | 13 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000809757900024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0090-8258 1095-6859 |
| IngestDate | Thu Oct 02 05:46:20 EDT 2025 Thu Apr 03 07:00:24 EDT 2025 Sat Nov 29 07:25:16 EST 2025 Tue Nov 18 21:46:42 EST 2025 Sun Apr 06 06:54:01 EDT 2025 Tue Feb 25 20:12:37 EST 2025 Tue Oct 14 19:27:52 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Copyright © 2022 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c466t-7f0450059f72d80a60bd6cdb8389dadcbb032f96fdbe12925dcb4f938e643d943 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 35031189 |
| PQID | 2620081882 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_2620081882 pubmed_primary_35031189 crossref_citationtrail_10_1016_j_ygyno_2021_12_028 crossref_primary_10_1016_j_ygyno_2021_12_028 elsevier_sciencedirect_doi_10_1016_j_ygyno_2021_12_028 elsevier_clinicalkeyesjournals_1_s2_0_S0090825821016966 elsevier_clinicalkey_doi_10_1016_j_ygyno_2021_12_028 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-03-01 |
| PublicationDateYYYYMMDD | 2022-03-01 |
| PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Gynecologic oncology |
| PublicationTitleAlternate | Gynecol Oncol |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Minion, Tewari (bb0085) 2018; 148 National Cancer Institute (bb0010) 2021 Subramanian, Trogdon, Ekwueme, Gardner, Whitmire, Rao (bb0065) 2010; 20 Abu-Rustum, Yashar, Bean, Bradley, Campos, Chon (bb0030) 2020; 18 Watanabe, Hoshiai, Nakanishi, Kawamura, Tanaka, Isaka (bb0090) 2011; 31 Pfaendler, Tewari (bb0040) 2016; 214 Vora, Gupta (bb0020) 2018; 3 Alholm, Monk, Ting, Pulgar, Boyd, Sudharshan (bb0045) 2021; 161 Insinga, Ye, Singhal, Carides (bb0055) 2008; 111 Parikh-Patel, Morris, Kizer (bb0115) 2017; 96 US Food and Drug Administration (FDA) (bb0100) 2018 Lairson, Fu, Chan, Xu, Shelal, Ramondetta (bb0050) 2017; 145 National Cancer Institute (bb0015) 2021 Friedman, Snyder, Zhou, Carducci, Buckley De Meritens, Corr (bb0080) 2020; 8 National Cancer Institute (bb0005) 2020 Marth, Landoni, Mahner, McCormack, Gonzalez-Martin, Colombo (bb0035) 2017; 28 Wright (bb0095) 2016 Harris, Brown, Lopez, Yap (bb0105) 2016; 13 Shao, He, Stein, Keefe (bb0110) 2020; 36 Doebele, Drilon, Paz-Ares, Siena, Shaw, Farago (bb0075) 2020; 21 Blanco, Chen, Melamed, Tergas, Khoury-Collado, Hou (bb0060) 2021; 224 Fagundes, Perez, Grigsby, Lockett (bb0025) 1992; 24 Chuang, Temin, Camacho, Duenas-Gonzalez, Feldman, Gultekin (bb0070) 2016; 2 Blanco (10.1016/j.ygyno.2021.12.028_bb0060) 2021; 224 Abu-Rustum (10.1016/j.ygyno.2021.12.028_bb0030) 2020; 18 Watanabe (10.1016/j.ygyno.2021.12.028_bb0090) 2011; 31 Pfaendler (10.1016/j.ygyno.2021.12.028_bb0040) 2016; 214 Shao (10.1016/j.ygyno.2021.12.028_bb0110) 2020; 36 Lairson (10.1016/j.ygyno.2021.12.028_bb0050) 2017; 145 Wright (10.1016/j.ygyno.2021.12.028_bb0095) 2016 Harris (10.1016/j.ygyno.2021.12.028_bb0105) 2016; 13 Vora (10.1016/j.ygyno.2021.12.028_bb0020) 2018; 3 Marth (10.1016/j.ygyno.2021.12.028_bb0035) 2017; 28 Alholm (10.1016/j.ygyno.2021.12.028_bb0045) 2021; 161 Doebele (10.1016/j.ygyno.2021.12.028_bb0075) 2020; 21 Minion (10.1016/j.ygyno.2021.12.028_bb0085) 2018; 148 US Food and Drug Administration (FDA) (10.1016/j.ygyno.2021.12.028_bb0100) 2018 National Cancer Institute (10.1016/j.ygyno.2021.12.028_bb0015) 2021 Subramanian (10.1016/j.ygyno.2021.12.028_bb0065) 2010; 20 Parikh-Patel (10.1016/j.ygyno.2021.12.028_bb0115) 2017; 96 National Cancer Institute (10.1016/j.ygyno.2021.12.028_bb0005) 2020 Fagundes (10.1016/j.ygyno.2021.12.028_bb0025) 1992; 24 Friedman (10.1016/j.ygyno.2021.12.028_bb0080) 2020; 8 Chuang (10.1016/j.ygyno.2021.12.028_bb0070) 2016; 2 National Cancer Institute (10.1016/j.ygyno.2021.12.028_bb0010) 2021 Insinga (10.1016/j.ygyno.2021.12.028_bb0055) 2008; 111 |
| References_xml | – volume: 214 start-page: 22 year: 2016 end-page: 30 ident: bb0040 article-title: Changing paradigms in the systemic treatment of advanced cervical cancer publication-title: Am. J. Obstet. Gynecol. – volume: 145 start-page: 108 year: 2017 end-page: 113 ident: bb0050 article-title: Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas publication-title: Gynecol. Oncol. – volume: 20 start-page: 400 year: 2010 end-page: 405 ident: bb0065 article-title: Cost of cervical cancer treatment: implications for providing coverage to low-income women under the Medicaid expansion for cancer care publication-title: Womens Health Issues – year: 2016 ident: bb0095 article-title: Management of recurrent or metastatic cervical cancer publication-title: UpToDate [Online Serial] Waltham, MA: UpToDate – volume: 31 start-page: 3063 year: 2011 end-page: 3067 ident: bb0090 article-title: Evaluation of oral etoposide in combination with cisplatin for patients with recurrent cervical cancer: long-term follow-up results of a Japanese multicenter study publication-title: Anticancer Res. – volume: 24 start-page: 197 year: 1992 end-page: 204 ident: bb0025 article-title: Distant metastases after irradiation alone in carcinoma of the uterine cervix publication-title: Int. J. Radiat. Oncol. Biol. Phys. – volume: 96 year: 2017 ident: bb0115 article-title: Disparities in quality of cancer care: the role of health insurance and population demographics publication-title: Medicine (Baltimore) – volume: 3 year: 2018 ident: bb0020 article-title: Targeted therapy in cervical cancer publication-title: ESMO Open. – volume: 111 start-page: 188 year: 2008 end-page: 196 ident: bb0055 article-title: Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large US health plan publication-title: Gynecol. Oncol. – year: 2021 ident: bb0015 article-title: Cancer Stat Facts: Cervical Cancer – volume: 36 start-page: 1187 year: 2020 end-page: 1194 ident: bb0110 article-title: Chemotherapy treatments, costs of care, and survival for elderly patients diagnosed with cervical cancer: an observational study publication-title: Curr. Med. Res. Opin. – volume: 161 start-page: 422 year: 2021 end-page: 428 ident: bb0045 article-title: Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: a community oncology-based analysis publication-title: Gynecol. Oncol. – volume: 21 start-page: 271 year: 2020 end-page: 282 ident: bb0075 article-title: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials publication-title: Lancet Oncol. – volume: 13 start-page: 171 year: 2016 end-page: 193 ident: bb0105 article-title: Immuno-oncology combinations: raising the tail of the survival curve publication-title: Cancer Biol. Med. – volume: 8 year: 2020 ident: bb0080 article-title: Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer publication-title: J. Immunother. Cancer. – volume: 28 year: 2017 ident: bb0035 article-title: Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann. Oncol. – volume: 148 start-page: 609 year: 2018 end-page: 621 ident: bb0085 article-title: Cervical cancer - state of the science: from angiogenesis blockade to checkpoint inhibition publication-title: Gynecol. Oncol. – year: 2018 ident: bb0100 article-title: Press Release: FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression During or After Chemotherapy – year: 2021 ident: bb0010 article-title: SEER*Explorer: Cervix Uteri Cancer Stage Distribution of SEER Incidence Cases, 2008-2017. Surveillance, Epidemiology, and End Results Program (SEER*Explorer) – volume: 224 start-page: e1 year: 2021 end-page: 11 ident: bb0060 article-title: Cost of care for the initial management of cervical cancer in women with commercial insurance publication-title: Am. J. Obstet. Gynecol. – volume: 2 start-page: 311 year: 2016 end-page: 340 ident: bb0070 article-title: Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline publication-title: J. Glob. Oncol. – year: 2020 ident: bb0005 article-title: Cancer Trends Progress Report: Cervical Cancer Screening – volume: 18 start-page: 660 year: 2020 end-page: 666 ident: bb0030 article-title: NCCN guidelines insights: cervical cancer, version 1.2020: featured updates to the NCCN guidelines publication-title: J. Natl. Compr. Cancer Netw. – volume: 2 start-page: 311 year: 2016 ident: 10.1016/j.ygyno.2021.12.028_bb0070 article-title: Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline publication-title: J. Glob. Oncol. doi: 10.1200/JGO.2016.003954 – volume: 20 start-page: 400 year: 2010 ident: 10.1016/j.ygyno.2021.12.028_bb0065 article-title: Cost of cervical cancer treatment: implications for providing coverage to low-income women under the Medicaid expansion for cancer care publication-title: Womens Health Issues doi: 10.1016/j.whi.2010.07.002 – year: 2016 ident: 10.1016/j.ygyno.2021.12.028_bb0095 article-title: Management of recurrent or metastatic cervical cancer – volume: 96 year: 2017 ident: 10.1016/j.ygyno.2021.12.028_bb0115 article-title: Disparities in quality of cancer care: the role of health insurance and population demographics publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000009125 – volume: 148 start-page: 609 year: 2018 ident: 10.1016/j.ygyno.2021.12.028_bb0085 article-title: Cervical cancer - state of the science: from angiogenesis blockade to checkpoint inhibition publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2018.01.009 – volume: 8 year: 2020 ident: 10.1016/j.ygyno.2021.12.028_bb0080 article-title: Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer publication-title: J. Immunother. Cancer. doi: 10.1136/jitc-2020-001126 – year: 2020 ident: 10.1016/j.ygyno.2021.12.028_bb0005 – volume: 111 start-page: 188 year: 2008 ident: 10.1016/j.ygyno.2021.12.028_bb0055 article-title: Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large US health plan publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2008.07.032 – volume: 145 start-page: 108 year: 2017 ident: 10.1016/j.ygyno.2021.12.028_bb0050 article-title: Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2017.02.011 – volume: 13 start-page: 171 year: 2016 ident: 10.1016/j.ygyno.2021.12.028_bb0105 article-title: Immuno-oncology combinations: raising the tail of the survival curve publication-title: Cancer Biol. Med. doi: 10.20892/j.issn.2095-3941.2016.0015 – volume: 24 start-page: 197 year: 1992 ident: 10.1016/j.ygyno.2021.12.028_bb0025 article-title: Distant metastases after irradiation alone in carcinoma of the uterine cervix publication-title: Int. J. Radiat. Oncol. Biol. Phys. doi: 10.1016/0360-3016(92)90671-4 – volume: 31 start-page: 3063 year: 2011 ident: 10.1016/j.ygyno.2021.12.028_bb0090 article-title: Evaluation of oral etoposide in combination with cisplatin for patients with recurrent cervical cancer: long-term follow-up results of a Japanese multicenter study publication-title: Anticancer Res. – year: 2021 ident: 10.1016/j.ygyno.2021.12.028_bb0010 – year: 2021 ident: 10.1016/j.ygyno.2021.12.028_bb0015 – volume: 214 start-page: 22 year: 2016 ident: 10.1016/j.ygyno.2021.12.028_bb0040 article-title: Changing paradigms in the systemic treatment of advanced cervical cancer publication-title: Am. J. Obstet. Gynecol. doi: 10.1016/j.ajog.2015.07.022 – volume: 224 start-page: e1 issue: 286 year: 2021 ident: 10.1016/j.ygyno.2021.12.028_bb0060 article-title: Cost of care for the initial management of cervical cancer in women with commercial insurance publication-title: Am. J. Obstet. Gynecol. – volume: 3 year: 2018 ident: 10.1016/j.ygyno.2021.12.028_bb0020 article-title: Targeted therapy in cervical cancer publication-title: ESMO Open. doi: 10.1136/esmoopen-2018-000462 – volume: 36 start-page: 1187 year: 2020 ident: 10.1016/j.ygyno.2021.12.028_bb0110 article-title: Chemotherapy treatments, costs of care, and survival for elderly patients diagnosed with cervical cancer: an observational study publication-title: Curr. Med. Res. Opin. doi: 10.1080/03007995.2020.1758928 – volume: 161 start-page: 422 year: 2021 ident: 10.1016/j.ygyno.2021.12.028_bb0045 article-title: Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: a community oncology-based analysis publication-title: Gynecol. Oncol. doi: 10.1016/j.ygyno.2021.03.002 – volume: 21 start-page: 271 year: 2020 ident: 10.1016/j.ygyno.2021.12.028_bb0075 article-title: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30691-6 – year: 2018 ident: 10.1016/j.ygyno.2021.12.028_bb0100 – volume: 28 year: 2017 ident: 10.1016/j.ygyno.2021.12.028_bb0035 article-title: Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx220 – volume: 18 start-page: 660 year: 2020 ident: 10.1016/j.ygyno.2021.12.028_bb0030 article-title: NCCN guidelines insights: cervical cancer, version 1.2020: featured updates to the NCCN guidelines publication-title: J. Natl. Compr. Cancer Netw. doi: 10.6004/jnccn.2020.0027 |
| SSID | ssj0003012 |
| Score | 2.4387264 |
| Snippet | Current treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients progressing beyond... AbstractBackgroundCurrent treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 645 |
| SubjectTerms | Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Female Health Care Costs Hematology, Oncology, and Palliative Medicine Humans Immunotherapy Middle Aged Neoplasm Recurrence, Local - drug therapy Obstetrics and Gynecology Retrospective Studies Uterine Cervical Neoplasms - drug therapy |
| Title | Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0090825821016966 https://www.clinicalkey.es/playcontent/1-s2.0-S0090825821016966 https://dx.doi.org/10.1016/j.ygyno.2021.12.028 https://www.ncbi.nlm.nih.gov/pubmed/35031189 https://www.proquest.com/docview/2620081882 |
| Volume | 164 |
| WOSCitedRecordID | wos000809757900024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1095-6859 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003012 issn: 0090-8258 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bT9swFLYKTIiXafd1F-RJe-uCWidx4kc0sZsEmgaT-mY5vkARpFXTMtjr_viOb2kHK9se9hJVTuwoPp-PP5-eC0Kvc8GEVDRPcpNWSSYKljBg9gkzWSYyI4mqhCs2URwclMMh-9zp_IixMBdnRV2Xl5ds8l9FDW0gbBs6-w_ibgeFBvgNQocriB2ufyf41st14UQ-cVk06yZEsTXegcN5fflqQyG9aox1i44BQB2PdU86fWITidjW6TKffX9Va-n1Z29cy19s9PvzxjHTYKoWiwLPcPa3zvnX3cqCP3DwER61kDuUJ9_gQ7_73WB8Pup9CUbcYK6Ak27rr7WjvYoFUpfQMuQBjzrYpzIPYEuXNCr12SZvaHpvdDjduTq-qm0QJxk4s66PNF8S8-TcyTnNQXsNfLWiawm24601tEGKnIF239j9uDf81G7ooANJTFjlXANvvHMLbcZRVvGbVecXx2OO7qG74QCCdz1w7qOOrh-gzf3gYvEQCY8fPKpxix8c8YNBjtjhB48NtvjBDj844gdb_OCIH-zwgyN-sMfPI_T13d7R2w9JqMORyIzSWVIY4P02StkURJV9QfuVolJVJZBdJZSsqn5KDKNGVRroI8mhKTMsLTXQXcWy9DFar8e1foqwYEYI0RdCVibrG82UVDorSKa0pFVadRGJs8dlSFJva6Wc8eiNeMrd7HM7-3xAOMx-F71pO018jpbbH8-iWHgMP4YNkwOybu9W_K6bbsLab_iAN_AkP4RjizW8lMQOxSjtItr2DLzW89U_v_JVRA0HrW__yhO1Hs8bbstI2GSUJemiJx5O7adHJD5beec52loszRdofTad65fojryYjZrpNlorhuV2WAQ_AQfU118 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trends+in+treatment+patterns+and+costs+of+care+among+patients+with+advanced+stage+cervical+cancer&rft.jtitle=Gynecologic+oncology&rft.au=Musa%2C+Fernanda+B&rft.au=Brouwer%2C+Elizabeth&rft.au=Ting%2C+Jie&rft.au=Schwartz%2C+Naomi+R+M&rft.date=2022-03-01&rft.eissn=1095-6859&rft.volume=164&rft.issue=3&rft.spage=645&rft_id=info:doi/10.1016%2Fj.ygyno.2021.12.028&rft_id=info%3Apmid%2F35031189&rft.externalDocID=35031189 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon |